ARA-290

Also known as: Cibinetide

ARA-290 (cibinetide) is an 11-amino acid peptide derived from the helix B domain of erythropoietin (EPO), designed to selectively activate the innate repair receptor (IRR), a heterodimer of the erythropoietin receptor (EPOR) and the common beta chain (CD131). Unlike full-length EPO, ARA-290 does not stimulate erythropoiesis or thrombopoiesis, as it lacks affinity for the homodimeric EPOR responsible for hematopoietic effects. Instead, it triggers anti-inflammatory, anti-apoptotic, and neuroprotective signaling pathways, primarily through PI3K/Akt and STAT3 activation, in tissues such as nerves, kidneys, and the heart. Key research findings from clinical trials indicate that ARA-290 reduces neuropathic pain and improves small nerve fiber function in patients with sarcoidosis and type 2 diabetes. In a randomized, placebo-controlled trial, it significantly decreased pain scores and increased corneal nerve fiber density, suggesting regenerative effects on peripheral nerves. Additional studies have shown benefits in reducing inflammation and oxidative stress in models of ischemia-reperfusion injury and diabetic nephropathy, with no observed adverse effects on red blood cell parameters. Clinically, ARA-290 is being investigated for conditions involving chronic inflammation and tissue damage, including diabetic neuropathy, sarcoidosis-associated small fiber neuropathy, and renal ischemia. Its lack of hematopoietic activity makes it a safer alternative to EPO for long-term tissue protection. However, larger phase III trials are needed to confirm efficacy and establish dosing protocols for specific indications. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides